Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of INCB099318 in participants with advanced solid tumors has been terminated. The update reports safety, tolerability, pharmacokinetics, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cutaneous Squamous Cell Carcinoma
• Esophageal Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Merkel Cell Carcinoma
• Nasopharyngeal Carcinoma
• Small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• INCB099318 (INCB099318)

Snippet

Sponsor: Incyte Corporation | Conditions: Advanced Solid Tumors, MSI-H/dMMR Tumors | Phase 1 | Status: TERMINATED